Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Shares Outstanding (2019 - 2025)

Maxcyte (MXCT) has disclosed Shares Outstanding for 6 consecutive years, with $106.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 1.28% to $106.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $106.6 million, a 1.28% increase, with the full-year FY2024 number at $105.7 million, up 1.68% from a year prior.
  • Shares Outstanding was $106.6 million for Q3 2025 at Maxcyte, roughly flat from $106.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $106.6 million in Q3 2025 to a low of $84.7 million in Q1 2021.
  • A 5-year average of $101.7 million and a median of $103.1 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: skyrocketed 30.78% in 2021, then increased 1.18% in 2022.
  • Maxcyte's Shares Outstanding stood at $101.2 million in 2021, then increased by 1.18% to $102.4 million in 2022, then rose by 1.53% to $104.0 million in 2023, then grew by 1.68% to $105.7 million in 2024, then rose by 0.88% to $106.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Shares Outstanding are $106.6 million (Q3 2025), $106.6 million (Q2 2025), and $106.3 million (Q1 2025).